Enlivex Ltd. ENLV
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $9.2M | $10.6M | $19.0M | $18.7M | $12.9M | $6.1M | $5.6M | $4.0M | $1.7M | $8.9M |
| SG&A | $5.8M | $4.9M | $6.1M | $7.1M | $6.4M | $3.7M | $3.0M | $1.3M | $480.0K | $5.9M |
| Total operating expenses | $15.0M | $15.9M | $29.4M | $25.8M | $19.3M | $9.8M | $8.6M | $5.3M | $2.2M | $15.9M |
| Operating income | -$15.0M | -$15.9M | -$29.4M | -$25.8M | -$19.3M | -$9.8M | -$8.6M | -$5.3M | -$2.2M | -$15.9M |
| Pre-tax income | $1.62B | -$15.0M | -$29.1M | — | $14.5M | $11.8M | $9.4M | $4.2M | $2.5M | -$15.8M |
| Income tax | $382.6M | — | — | — | — | — | — | $4.0K | $28.0K | $216.0K |
| Net income | $1.24B | -$15.0M | -$29.1M | -$31.1M | -$14.5M | -$11.8M | -$9.4M | -$4.2M | -$2.5M | -$16.0M |
| EPS, basic | 27.04 | -0.73 | -1.56 | -1.69 | -0.81 | -0.90 | — | — | — | — |
| EPS, diluted | 25.48 | -0.73 | -1.56 | -1.69 | -0.81 | -0.90 | -1.11 | -1.40 | -0.94 | -40.13 |
| Shares, diluted (wtd. avg.) | 48.5M | 20.5M | 18.6M | 18.4M | 17.9M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.9M | $3.3M | $1.2M | $50.4M | $11.6M | $7.0M | $5.5M | $9.8M | $9.0M | $3.0M |
| Short-term investments | — | $198.0K | $5.1M | — | $62.9M | — | — | — | — | — |
| Receivables | — | — | — | — | — | — | — | $16.0K | $28.0K | $52.0K |
| Total current assets | $1.74B | $26.0M | $33.8M | $52.3M | $86.4M | $38.1M | $16.4M | $10.3M | $3.6M | $10.5M |
| Property, plant and equipment | $361.0K | $625.0K | $1.5M | $9.9M | $2.5M | $1.5M | $648.0K | $685.0K | $388.0K | $71.0K |
| Total assets | $2.33B | $27.7M | $36.8M | $67.6M | $95.1M | $40.4M | $17.6M | $11.0M | $3.6M | $10.6M |
| Total current liabilities | $9.0M | $3.8M | $6.1M | $6.6M | $4.7M | $4.4M | $6.0M | $1.1M | $460.0K | $1.9M |
| Total liabilities | $392.1M | $4.1M | $6.7M | $10.8M | $10.1M | $4.9M | $6.3M | $1.3M | $1.0M | — |
| Retained earnings | $1.11B | -$127.1M | -$112.1M | -$83.0M | -$52.0M | -$37.5M | -$25.7M | -$16.3M | -$45.8M | -$39.8M |
| Total equity | $1.93B | $23.6M | $30.1M | $56.8M | $85.0M | $35.5M | $11.3M | $9.7M | $8.5M | $2.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.4M | -$13.0M | -$23.5M | -$24.0M | -$17.5M | -$11.0M | -$7.0M | -$3.2M | -$2.3M | -$15.5M |
| Depreciation and amortisation | $332.0K | $545.0K | $835.0K | $777.0K | $546.0K | $286.0K | $206.0K | $121.0K | $83.0K | $38.0K |
| Stock-based compensation | $1.8M | $2.1M | $2.0M | $2.7M | $2.9M | $670.0K | $810.0K | $1.0M | $121.0K | $700.0K |
| Capital expenditure | $68.0K | $103.0K | $236.0K | $8.1M | $1.6M | $1.0M | $193.0K | $461.0K | $130.0K | $18.0K |
| Investing cash flow | -$1.3M | $9.1M | -$26.0M | $62.5M | -$38.4M | -$21.0M | -$6.4M | -$501.0K | -$130.0K | $9.0M |
| Financing cash flow | $10.4M | $6.5M | $360.0K | $150.0K | $61.0M | $33.1M | $8.3M | $5.2M | $8.1M | $6.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-033857.
Plot the figures US dollars
No annual figures to plot for this company yet.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |